Global Ovarian Cancer Major Players 2025, Forecast To 2034
26 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Ovarian Cancer Market?
The ovarian cancer market has seen considerable growth due to a variety of factors.
• The expansion of the ovarian cancer market has been astronomical in the past few years. It's projected to rise from $3.67 billion in 2024 to $4.36 billion in 2025, marking a compound annual growth rate (CAGR) of 18.9%.
The significant growth observed in the past can be linked to factors such as growing elderly population, rising ovarian cancer incidents, increasing rate of ovarian cancer prevalence, enhancement in government measures, and increase in healthcare expenditure.
What Is The Projected Growth Of The Ovarian Cancer Template Market?
The ovarian cancer market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of ovarian cancer is predicted to witness remarkable growth in the coming years, rising to $8.61 billion by 2029, with a compound annual growth rate (CAGR) of 18.5%.
Several factors are contributing to the expected growth in this forecast period, such as intensified research on personalized medicine and targeted therapies, an aging population, increased awareness about healthcare, a surge in ovarian cancer incidence, and climbing healthcare expenditures. Notable trends for the forecast period include cutting-edge therapies, improvements in radiation therapy practices, development in healthcare infrastructure, technological progress, and the adoption of innovative drugs.
What Are The Key Drivers Fueling Growth In The Ovarian Cancer Market?
The anticipated growth in the market for ovarian cancer treatment can be attributed to the escalating female population. This demographic is defined by the quantum of women inhabiting a particular region or globally at any given period. Factors leading to the surge in female population comprise of prolonged life expectancy, enhanced health care, and changes in demographic patterns. Ovarian cancer patient care benefits the female populace by supplying procedures like surgery, chemotherapy, targeted therapy, and immunotherapy to eradicate malignant cells, decelerate disease progression, reduce symptoms, and ameliorate survival rates, eventually promoting a superior quality of life and optimism for improved prospects in the long term. To exemplify, in March 2024, data from the Census Bureau, an agency of the US government, estimated that there were roughly 168 million women in the US as of July 2022. In addition, the figure for women aged 85 and above was around 1.9 million more. Moreover, in December 2022, a publication by CEIC Data, a British financial service firm, recorded that the number of women between the ages of 15-64 reached 2,951,856 in 2022, witnessing an increment from 2,940,645 in 2021. Hence, the inflating female population is fuelling the expansion of the ovarian cancer market.
What Are The Principal Market Segments In The Global Ovarian Cancer Industry?
The ovarian cancer market covered in this report is segmented –
1) By Type: Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma
2) By Treatment: Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, Surgery
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-user: Hospitals, Diagnostic Centers, Drug Stores, Online Pharmacies, Other End Users
Subsegments:
1) By Epithelial Ovarian Tumors: Serous Carcinoma, Mucinous Carcinoma, Endometrioid Carcinoma, Clear Cell Carcinoma, Brenner Tumors
2) By Ovarian Germ Cell Tumors: Dysgerminoma, Teratoma, Yolk Sac Tumor, Embryonal Carcinoma, Choriocarcinoma
3) By Ovarian Stromal Tumors: Granulosa Cell Tumors, Thecomas, Sertoli-Leydig Cell Tumors
4) By Primary Peritoneal Carcinoma: High-Grade Serous Carcinoma, Low-Grade Serous Carcinoma
What Trends Are Reshaping The Future Of The Ovarian Cancer Market?
Key players in the ovarian cancer industry are focusing their efforts on advanced technologies, such as AI platforms, to effectively process complex medical data. Ovarian cancer AI platforms are technologically advanced systems that utilize artificial intelligence (AI) and machine learning (ML) to improve different facets of ovarian cancer treatments. These platforms commonly incorporate medical imaging, genomic data, electronic health records (EHRs), and real-time analytics to aid in early detection, accurate diagnosis, custom treatment plans, and patient monitoring. For example, in February 2024, AIIMS Delhi partnered with CDAC Pune, an organization based in India, to introduce iOncology.ai, a homegrown AI platform for early detection of breast and ovarian cancer. This platform applies deep learning paradigms to scrutinize radiological and histopathological images with high precision, aiming to enhance early diagnosis and improve survival rates. Already being used in several hospitals, iOncology.ai dovetails with the healthcare ecosystem to offer risk evaluations and suggest mammograms, especially for women in rural regions. It is part of a larger initiative to incorporate AI into healthcare and alleviate the burden on medical systems.
Who Are the Key Players In The Ovarian Cancer Market?
Major companies operating in the ovarian cancer market are:
• Pfizer Incorporated
• Johnson & Johnson Services Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer Aktiengesellschaft
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Novogen Limited
• Oasmia Pharmaceutical AB
• Clovis Oncology Inc.
• Aeterna Zentaris Inc.
• Allarity Therapeutics Inc.
• Ellipses Pharma Ltd.
What Are The Regional Insights Into The Ovarian Cancer Market?
North America was the largest region in the ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.